Calix[4]arene α-hydroxymethylphosphonic acids as potential inhibitors of protein tyrosine phosphatases

Authors

  • V. V. Trush Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine
  • V. Yu. Tanchuk Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine
  • S. O. Cherenok Institute of Organic Chemistry of the NAS of Ukraine, Ukraine
  • V. I. Kalchenko Institute of Organic Chemistry of the NAS of Ukraine, Ukraine
  • A. I. Vovk Institute of Bioorganic Chemistry and Petrochemistry of the NAS of Ukraine, Ukraine

DOI:

https://doi.org/10.24959/ophcj.14.782

Keywords:

protein tyrosine phosphatases, inhibitors, calixarenes, docking

Abstract

Calix[4]arene are known to be a promising scaffold for designing inhibitors of protein tyrosine phosphatases.
In this work calix[4]arene mono- and bis-α-hydroxymethylphosphonic acids have been tested in vitro for the inhibitory activity against some therapeutically important protein tyrosine phosphatases. The results obtained have shown that these macrocyclic compounds can inhibit CD45, PTP1B, and SHP2 with IC50 values in the micromolar range. At the same time the inhibitors have demonstrated lower activity toward other protein tyrosine phosphatases such as TC-PTP and PTPβ. It has been found that mono-substituted calix[4]arene is more potent inhibitor of CD45 than the bis-substituted one and shows about 2-15 fold selectivity over TC-PTP, PTPβ, SHP2 and PTP1B. Model 4-hydroxyphenyl-α-hydroxymethylphosphonate displays at least one order lower activity than the phosphonate derivatives of calix[4]arene. Thus, the combination of a macrocyclic platform and α-hydroxymethylphosphonate group is essential for the inhibition activities of these compounds. Computer-simulated docking studies have been performed using AutoDock 4.2 programme by the example of PTP1B. The data obtained indicate that the inhibitors can bind in the active site of the enzyme. To clarify the inhibition mechanism the possible enzyme-inhibitor complexes have been considered using several crystal structures of PTP1B and all stereoisomeric forms of the inhibitors.

Downloads

Download data is not yet available.

References

  1. Vintonyak V.V., Antonchick A.P., Rauh D. et al. Curr. Opin. Chem. Biol., 2009, Vol. 13, pp.272-283.
  2. Alonso A., Sasin J., Bottini N. et al. Cell., 2004, Vol. 117, pp.699-711.
  3. Hunter T. Cell., 2004, Vol. 100, pp.113-127.
  4. Elchebly M., Payette P., Michaliszyn E. et al. Science, 1999, Vol. 283, pp.1544-1548.
  5. Klaman L.D., Boss O., Peroni O.D. et al. Mol. Cell Biol., 2000, Vol. 20, No.15, pp.5479-5489.
  6. Lund I.K., Hansen J.A., Andersen H.S. et al. J. Mol. Endocrinol., 2005, Vol. 34, No.2, pp.339-351.
  7. Wang S., Yu W.-M., Zhang W. et al. J. Biol. Chem., 2009, Vol. 284, No.2, pp.913-920.
  8. Chan G., Kalaitzidis D., Neel B.G. Cancer Metastasis Rev., 2008, Vol. 27, No.2, pp.179-192.
  9. Hatakeyama M. Nat. Rev. Cancer., 2004, Vol. 4, pp.688-694.
  10. Koretzky G.A., Picus J., Thomas M.L. et al. Nature., 1990, Vol. 346, pp.66-68.
  11. Justement L.B., Campbell K.S., Chien N.C. et al. Science, 1991, Vol. 252, pp.1839-1842.
  12. Mustelin T., Coggeshall K.M., Altman A. Proc. Natl. Acad. Sci., 1989, Vol. 86, pp.6302-6306.
  13. Desai D.M., Sap J., Silvennoinen O. et al. EMBO J., 1994, Vol. 13, pp.4002-4010.
  14. Lazarovits A.I., Visser L., Asfar S. et al. Kidney Int., 1999, Vol. 55, pp.1303-1310.
  15. Sansone F., Segura M., Ungaro R. Dodrecht: Kluwer Academic Publishers, 2001, pp.496-512.
  16. Vicens J., Harrowfield J., Baklouti L. Dodrecht: Springer, 2007, pp.395-340.
  17. Perret F., Lazar A.N., Coleman A.W. Chem. Commun., 2006, pp.2425-2438.
  18. Guo D.-D., Wang K., Liu Y. J. Incl. Phenom. Macrocycl. Chem., 2008, Vol. 62, pp.1-21.
  19. Casnati A., Fabbi M., Pelizzi N. et al. Bioorg. Med. Chem. Lett., 1996, Vol. 6, pp.2699-2704.
  20. Dibama H.M., Clarot I., Fontanay S. et al. Bioorg. Med. Chem. Lett., 2009, Vol. 19, pp.2679-2682.
  21. Patel M.B., Modi N.R., Raval J.P. et al. Org. Biomol. Chem., 2012, Vol. 10, pp.1785-1789.
  22. Tsou L.K., Dutschman G.E., Gullen E.A. et al. Bioorg. Med. Chem. Lett., 2010, Vol. 20, pp.2137-2139.
  23. Mourer M., Psychogios N., Laumond G. et al. Bioorg. Med. Chem., 2010, Vol. 18, pp.36-40.
  24. Menger F.M., Bian J., Sizova E. et al. Org. Lett., 2004, Vol. 6, pp.261-264.
  25. Shimojo K., Oshima T., Naganawa H. et al. Biomacromolecules, 2007, Vol. 8, pp.3061-3066.
  26. Rodik R.V., Boyko V.I., Kalchenko V.I. Curr. Med. Chem., 2009, Vol. 16, pp.1630-1655.
  27. Li X., Bhandari A., Holmes C. P. et al. Bioorg. Med. Chem. Lett., 2004, Vol. 14, pp.4301-4305.
  28. Wang Q., Zhu M., Zhu R. et al. Eur. J. Med. Chem., 2012, Vol. 49, pp.354-360.
  29. Vovk A.I., Kalchenko V.I., Cherenok S.O. et al. Org. Biomol. Chem., 2004, Vol. 2, pp.3162-3166.
  30. Vovk A.I., Kononets L.A., Tanchuk V.Yu. et al. J. Incl. Phenom. Macrocycl. Chem., 2010, Vol. 66, pp.271-276.
  31. Cherenok S.O., Vovk A.I., Muravyova I.V. et al. Org. Lett., 2006, Vol. 8, pp.549-556.
  32. Vovk A.I., Kononets L.A., Tanchuk V.Yu. et al. Bioorg. Med. Chem. Lett., 2010, Vol. 20, pp.483-485.
  33. Trush V.V., Cherenok S.O., Tanchuk V.Yu. et al. Bioorg. Med. Chem. Lett., 2013, Vol. 23, No.22, pp.5619-5623.
  34. Patel D.V., Rielly-Gauvin K., Ryono D.E. et al. J. Med. Chem., 1995, Vol. 38, pp.4557-4569.
  35. Bubenik M., Preville P., Dugas J. et al. Tetrahedron Lett., 2003, Vol. 44, pp.8261-8263.
  36. Patel R.N., Banerjee A., Szarka L.J. Tetrahedron: Asymmetry, 1997, Vol. 8, pp.1055-1059.
  37. Patel D.V., Rielly-Gauvin K., Ryono D.E. Tetrahedron Lett., 1990, Vol. 31, pp.5587-5590.
  38. Frechette R.F., Ackerman C., Beers S. et al. Bioorg. Med. Chem. Lett., 1997, Vol. 7, No.17, pp.2169-2172.
  39. Cherenok S.O., Yushchenko O.A., Tanchuk V.Yu. et al. Arkivok, 2012, Vol. 4, pp.278-280.
  40. Tonks N.K. FEBS Lett., 2003, Vol. 546, pp.140-148.
  41. Denu J.M., Dixon J.E. Curr. Opin. Chem. Biol., 1998, Vol. 2, pp.633- 641.
  42. Kamerlin S.C.L., Rucker R., Boresch S. Biochem. Biophys. Res. Comm., 2006, Vol. 345, pp.1161-1166.
  43. Tanchuk V.Y., Tanin V.O., Vovk A.I. Chem. Biol. Drug Des., 2012, Vol. 80, pp.121-124.
  44. Huey R., Morris G.M., Olson A.J. et al. J. Comput. Chem., 2007, Vol. 28, No.6, pp.1145-1152.

Downloads

Published

2014-03-06

How to Cite

(1)
Trush, V. V.; Tanchuk, V. Y.; Cherenok, S. O.; Kalchenko, V. I.; Vovk, A. I. Calix[4]arene α-Hydroxymethylphosphonic Acids As Potential Inhibitors of Protein Tyrosine Phosphatases. J. Org. Pharm. Chem. 2014, 12, 39-42.

Issue

Vol. 12 No. 1(45) (2014)

Section

Original Researches

License

Copyright (c) 2014 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).